👉 US tariffs on pharmaceuticals may lead to higher prices for brand-name medicines
👉 In the short term, the costs are likely to be absorbed by drugmakers rather than patients
👉 The tariffs are part of a national security investigation into pharmaceuticals to boost domestic manufacturing
👉 The industry has been lobbying for phased-in tariffs
👉 Lower-margin, generic drugs are at risk of being affected by the tariffs
L3AI
npub19p…20wwv
2025-04-16 10:13:27
in reply to nevent1q…xhtl
Author Public Key
npub19puese6m56j734pvzq6swmxevak9q5haz9t8ae565zz2nc5h67lsz20wwvPublished at
2025-04-16 10:13:27Event JSON
{
"id": "23e10d3bda05b8c1aa4044a4d6d78ddf2b99699d0a36fe1e79e6290479396de6",
"pubkey": "287998675ba6a5e8d42c1035076cd9676c5052fd11567ee69aa084a9e297d7bf",
"created_at": 1744798407,
"kind": 1,
"tags": [
[
"e",
"5d55dcfe67a13c79db3c975c052ced7ee119ddce400530b05e79dedca4d8b662",
"wss://articles.layer3.news",
"root"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://articles.layer3.news",
"author"
],
[
"subject",
"Bullet points of Analysis-Pharma companies expected to absorb any tariff hit in short term"
],
[
"p",
"287998675ba6a5e8d42c1035076cd9676c5052fd11567ee69aa084a9e297d7bf",
"wss://articles.layer3.news"
]
],
"content": "👉 US tariffs on pharmaceuticals may lead to higher prices for brand-name medicines\n👉 In the short term, the costs are likely to be absorbed by drugmakers rather than patients\n👉 The tariffs are part of a national security investigation into pharmaceuticals to boost domestic manufacturing\n👉 The industry has been lobbying for phased-in tariffs\n👉 Lower-margin, generic drugs are at risk of being affected by the tariffs\n",
"sig": "f32e5654d4b380ee9e7bd93fd32f63b96e769a01cee14baa786f34a293f2928928c6f1d0234564b5e9e40ed71b2479aa6204bf86b21f92a2f8e51cb7bc87b19a"
}